tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Outlook Therapeutics price target lowered to 50c from $1 at H.C. Wainwright
PremiumThe FlyOutlook Therapeutics price target lowered to 50c from $1 at H.C. Wainwright
15d ago
Morning Movers: Baidu jumps following proposed spinoff of Kunlunxin
Premium
The Fly
Morning Movers: Baidu jumps following proposed spinoff of Kunlunxin
15d ago
FDA Issues New Setback for Outlook Therapeutics’ LYTENAVA
Premium
Company Announcements
FDA Issues New Setback for Outlook Therapeutics’ LYTENAVA
15d ago
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
18d ago
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—12/24/25
Premium
Market News
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—12/24/25
24d ago
Outlook Therapeutics: Strengthened Case for ONS-5010 Drives Attractive Risk/Reward and Increased $10 Price Target
Premium
Ratings
Outlook Therapeutics: Strengthened Case for ONS-5010 Drives Attractive Risk/Reward and Increased $10 Price Target
24d ago
Outlook Therapeutics’ FDA Review for ONS-5010 Resubmission
PremiumCompany AnnouncementsOutlook Therapeutics’ FDA Review for ONS-5010 Resubmission
2M ago
Outlook Therapeutics announces acceptance of BLA for ONS-5010
Premium
The Fly
Outlook Therapeutics announces acceptance of BLA for ONS-5010
2M ago
Outlook Therapeutics Resubmits Biologics License Application
Premium
Company Announcements
Outlook Therapeutics Resubmits Biologics License Application
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100